Achievement of maximal SARS-CoV-2 collective immunity among the Tajik population by March 2022

Despite all efforts of the world community, the COVID-19 pandemic remains one of the main epidemiological challenges of our time. Even with its widespread distribution, the infection may have certain local features due to social, geographic, and climatic factors. Objective: to study collective immunity to SARS-CoV-2 in the population of the Republic of Tajikistan.

A cross-sectional, randomized study of herd immunity was carried out according to a program developed by Rospotrebnadzor and the St. Petersburg Pasteur Institute, taking into account WHO recommendations. The ethics committees of the corresponding entities approved the study: Tajik Ministry of Health and Social Protection; and the St. Petersburg Pasteur Institute (Russia). Based on questionnaire results, 4,022 people were selected, representing 0.15% (95% CI: 0.14-0.15) of the total population randomized by age and region. In subsequent laboratory analysis, 3682 people took part. The distribution and quantitative content of antibodies (Abs) to viral nucleocapsid (N Ag) and receptor binding domain (RBD Ag) were determined by ELISA. When questioned, a history of SARS-CoV-2 vaccination was indicated by 69.7% (95% CI: 68.2-71.2) of the volunteer cohort. Vector vaccines were most frequently used (50.6%; 95% CI: 48.7-52.5), with whole-virion inactivated preparations in second place (23.0%: 95% CI: 21.4-26.6) and mRNA vaccines in third place (21.0%; 95% CI:19.4-22.6).

The cohort (n = 3682) featured 27.5% men and 72.5% women. The overall seroprevalence was 98.5% (95% CI: 97.7-99.2) in men and 99.4% (95% CI: 99.0-99.6) in women (differences statistically insignificant). Overall seroprevalence in the cohort was 99.2% (95% CI: 98.8-99.4) and ranged from 97.2 to 100% in certain subgroups. Asymptomatic seropositivity in the whole cohort was 98.4% (95% CI: 97.6-99.1). As a result of a mandatory vaccination program introduced in Tajikistan under a COVID-19 Emergency Project, the level of herd immunity among vaccinated individuals reached 99.5% (95% CI: 99.1-99.7), which is similar to the level reached in the cohort as a whole.

The epidemic situation that developed in Tajikistan by mid-March 2022 was characterized by an almost absolute level of herd immunity, as evidenced by an absence of detected overt COVID-19 cases since the end of February (2022).

1. Agresti A., Coull B.A. Approximate is better than “exact” for interval estimation of binomial proportions. Am. Stat., 1998, Vol. 52, no. 2, pp. 119-126.

2. Amit S., Beni S.A., Biber A.; Grinberg A., Leshem E., Regev-Yochay G. Postvaccination COVID-19 among Healthcare Workers, Israel. Emerg. Infect. Dis., 2021, Vol. 27, no. 4, pp 1220-1222.

3. Batrakova L.G. Theory of .statistic. Мoscow: Knorus, 2016. 528 p.

4. Bioversity International. Available at: http://centralasia.bioversityinternational.org/tadzhikistan/ (Acessed 20/08/2022).

5. Brosh-Nissimov T., Maor Y., Elbaz M., Lipman-Arens S., Wiener-Well Y., Hussein K., Orenbuch-Harroch E., Cohen R., Zimhony O., Chazan B., Nesher L., Rahav G., Zayyad H., Hershman-Sarafov M., Weinberger M., Najjar-Debbiny R., Chowers M. Hospitalised patients with breakthrough COVID-19 following vaccination during two distinct waves in Israel, January to August 2021: a multicentre comparative cohort study. Euro. Surveill., 2022, Vol. 27, no. 20, 2101026. doi: 10.2807/1560-7917.ES.2022.27.20.2101026.

6. Dagan N., Barda N., Kepten E., Miron O., Perchik S., Katz M.A., Hernán M.A., Lipsitch M., Reis B., Balicer R.D. BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. N. Engl. J. Med., 2021, Vol. 384, no. 15, pp.1412-1423.

7. Emergency Project COVID-19. Available at: https://projects.worldbank.org/en/projects-operations/project-detail/P173765 Accessed. 20/08/2022.

8. Fischer A. Resistance of children to Covid-19. How? Mucosal Immunol., 2020, Vol. 13, no. 4, pp 563-565.

9. Haas E.J., Angulo F.J., McLaughlin J.M., Anis E., Singer S.R., Khan F., Brooks N., Smaja M., Mircus G., Pan K., Southern J., Swerdlow D.L., Jodar L., Levy Y., Alroy-Preis S. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet, 2021, Vol. 397, no. 10287, pp. 1819-1829.

10. Harrison D., Muradali K., El Sahly H., Bozkurt B., Jneid H. Impact of the SARS-CoV-2 pandemic on health-care workers. Hosp. Pract. (1995), 2020, Vol. 48, no. 4, pp.161-164.

11. Huang Q., Zeng J., Yan J. COVID-19 mRNA vaccines. J. Genet. Genomics, 2021, Vol. 48, no 2, pp 107-114.

12. Johns Hopkins University’s Center for Systems Science and Engineering (CSSE) COVID-19 Data Repository. Available at: https://github.com/CSSEGISandData/COVID-19. Accessed 23/08/2022.

13. Khan W.H., Hashmi Z., Goel A., Ahmad R., Gupta K., Khan N., Alam I., Ahmed F., Ansari M.A. COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions. Review. Front. Cell. Infect. Microbiol., 2021, Vol. 11, 690621. doi: 10.3389/fcimb.2021.690621.

14. Mehta N.S., Mytton O.T., Mullins E.W.S., Fowler T.A., Falconer C.L., Murphy O.B., Langenberg C., Jayatunga W.J.P., Eddy D.H., Nguyen-Van-Tam J.S. SARS-CoV-2 (COVID-19): What do we know about children? A systematic review. Clin. Infect. Dis., 2020, Vol 71, no. 9, pp. 2469-2479.

15. Moriyama M., Hugentobler W.J., Iwasaki A. Seasonality of Respiratory Viral Infections. Annu.Rev. Virol., 2020. Vol. 7, no. 1, pp 83-101.

16. Mukhabbatov Kh.M. Natural resource potential of the mountainous regions of Tajikistan. Moscow: Granitca, 1999.

17. Opoku M.M., Asante K.P., Gyaase S., Teviu E.A.A., Amponsah K., Twum A., Kusi K.F., Ampofo A.K., Adomako-Boateng F. Risk factors for COVID-19 virus infection among health workers: a case-control study in the bono east region of ghana. Am. J. Infect. Control, 2022. doi: 10.1016/j.ajic.2022.08.008.

18. Our world is in data. Available at: https://ourworldindata.org/ (Accessed 23/08/2022).

19. Popova A.Y., Kasymov O.T., Smolenski V.Y., Smirnov V. S., Egorova S.A., Nurmatov Z.S., Milichkina A.M., Suranbaeva G.S., Kuchuk T.E., Khamitova I.V., Zueva E.V., Ivanov V.A., Nuridinova Z.N., Derkenbaeva A.A., Drobyshevskaya V.G., Sattarova G.Z., Kaliev M.T., Gubanova A.V., Zhimbaeva O.B., Razumovskaya A.P., Verbov V.N., Likhachev I.V., Krasnov A.V., Totolian A.A. SARS CoV 2 herd immunity of the Kyrgyz population in 2021. Medical Microbiology and Immunology, 2022. Vol. 211, no. 4, pp. 195-210.

20. Popova A.Yu., Totolian A.A. Methodology for assessing herd immunity to the SARS-CoV-2 virus in the context of the COVID-19 pandemic. Russian Journal of Infection and Immunity, 2021, Vol 11, no. 4, pp. 609-616. (In Russ.). doi:10.15789/2220-7619-MFA-1770.

21. Popova A.Yu., Andreeva E.E., Babura E.A., Balakhonov S.V., Bashketova N.S., Bugorkova S.A., Bulanov M.V., Valeullina N.N., Goryaev D.V., Detkovskaya N.N., Ezhlova E.B., Zhimbaeva O.B., Zaitseva N.N., Zueva E.V., Ivanov V.A., Istorik O.A., Kovalchuk I.V., Kozlovskikh D.N., Kombarova S.Yu., Kurganova O.P., Lomovtsev A.E., Lukicheva L.A., Melnikova A.A., Mikailova O.M., Milichkina A.M., Noskov A.K., Noskova L.N., Oglezneva E.E., Osmolovskaya T.P., Patyashina M.A., Penkovskaya N.A., Petrova O.A., Razumovskaya A.P., Samoilova L.V., Stepanova T.F., Trotsenko O.E., Khamitova I.V., Totolian A.A. Peculiarities of SARS-CoV-2 nucleocapsid in children during the COVID-19 epidemic of 2020. Pediatrics. Journal named after G. Speransky, 2021, Vol. 100, no. 3, pp. 97-106. (In Russ.)

22. Popova A.Yu., Andreeva E.E., Babura E.A., Balakhonov S.V., Bashketova N.S., Bulanov M.V., Valeullina N.N., Goryaev D.V., Detkovskaya N.N., Ezhlova E.B., Zaitseva N.N., Istorik O.A., Kovalchuk I.V., Kozlovskikh D.N., Kombarova S.V., Kurganova O.P., Kutyrev V.V., Lomovtsev A.E., Lukicheva L.A., Lyalina L.V., Melnikova A.A., Mikailova O.M., Noskov A.K., Noskova L.N., Oglezneva E.E., Osmolovskaya T.P., Patyashina M.A., Penkovskaya N.A., Samoilova L.V., Smirnov V.S., Stepanova T.F., Trotsenko O.E., Totolian A.A., Features of developing SARS-CoV-2 nucleocapsid protein population-based seroprevalence during the first wave of the COVID-19 epidemic in the Russian Federation. Russian Journal of Infection and Immunity, 2021. Vol. 11, no. 2, pp. 297-323. (In Russ.). doi: 10.15789/2220-7619-FOD-1684.

23. Popova A.Yu., Smirnov V.S., Ezhlova E.B., Melnikova A.A., Samoilova L.V., Lyalina L.V., Semyonova E.V., Gursky M.A., Aksenova E.A., Arbuzova T.V., Totolian A.A. Herd immunity to SARS-CoV-2 in the Novosibirsk Region population amid the COVID-19 pandemic. Problems of Virology, 2021, Vol. 66, no. 4, pp 299-309. (In Russ.)

24. Popova A.Yu., Smirnov V.S., Ezhlova E.B., Melnikova A.A., Trotsenko O.E., Kurganova O.P., Detkovskaya T.N., Lyalina L.V., Abbasova E.I., Yurgina O.M., Romanova O.B., Pyatyrova E.V., Burdinskaya E.N., Solokhin A.S., Bogdan E.V., Bazykina E.A., Totolian A.A. Herd immunity to SARS-CoV-2 in the population of the Southern regions of the Far East of Russia. Acta Biomedica Scientifica, 2021, Vol. 6, no. 5, pp. 253-273. (In Russ.)

25. Qi H., Xiao S., Shi R., Ward M.P., Chen Y., Tu W., Su Q., Wang W., Wang X., Zhang Z. COVID-19 transmission in Mainland China is associated with temperature and humidity: A time-series analysis. Sci.Tot. Environ, 2020, Vol. 728, 138778. doi: 10.1016/j.scitotenv.2020.138778.

26. Randolph H.E., Barreiro L.B. Herd Immunity: Understanding COVID-19. Immunity, 2020, Vol. 52, pp. 737-741.

27. Ross Business Consulting. Available at: https://www.rbc.ru/society/03/07/2021/60e074ad9a79479afe3d257b (Accessed 20/08/2022).

28. Rostami A., Sepidarkish M., Leeflang M.M.G., Riahi S.M., Shiadeh M.N., Esfandyari S., Mokdad A.H., Hotez P.J., Gasser R.B. SARS-CoV-2 seroprevalence worldwide: A systematic review and meta-analysis. Clin. Microbiol. Infect., 2020, Vol. 27, pp. 331-340.

29. Ryzhikov A.B., Ryzhikov Е.А., Bogryantseva M.P., Usova S.V., Danilenko E.D., Nechaeva E.A., Pyankov O.V., Pyankova O.G., Gudymo A.S., Bodnev S.A., Onkhonova G.S. Sleptsova E.S., Kuzubov V.I., Ryndyuk N.N., Ginko Z.I., Petrov V.N., Moiseeva A.A., Torzhkova P.Yu., Pyankov S.A., Tregubchak T.V., Antonec D.V., Gavrilova E.V., Maksyutov R.A. A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the “EpiVacCorona” Vaccine for the prevention of COVID-19, in volunteers aged 18-60 years (phase I-II). Russian Journal of Infection and Immunity, 2021, Vol. 11, no 2, pp. 283-296. (In Russ.). doi: 10.15789/2220-7619-ASB-1699.

30. Sakurai F., Tachibana M., Mizuguchi H. Adenovirus vector-based vaccine for infectious diseases. Drug Metab. Pharmacokinet., 2022, Vol. 42, 100432. doi: 10.1016/j.dmpk.2021.100432.

31. Smirnov V.S., Lyalina L.V., Milichkina A.M., Khamitova I.V., Zueva E.V., Ivanov V.A., Zaguzov V.S., Totolian A.A. Longitudinal Randomized Cohort Study of SARS-CoV-2 Antibody Seroprevalence in the St. Petersburg Population. Viruses, 2022, Vol. 14, no. 5, 913. doi: 10.3390/v14050913.

32. United Nations Department of Economic and Social Affairs. Available at: https://countrymeters.info/ru/Tajikistan. (Accessed 20/08/2022).

33. Wald A., Wolfowitz J. Confidence limits for continuous distribution functions. Ann. Math. Stat., 1939, Vol. 10, no. 2, pp. 105-118.

34. WHO population-based age-stratified seroepidemiological investigation protocol for coronavirus 2019 (COVID-19) infection, version 2, 26.05.2020. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Seroepidemiology-2020.2 Accessed 05/03/2022.

35. World bank. Statistic. Available at: https://data.worldbank.org/country/tajikistan. (Accessed 25/03/2022).